Multimedia
Drug diversion risk mitigation practices vital for health care organizations
Presented by Janice Ahlstrom, FHIMSS, CPHIMS, CCSFP, RN, BSN, Director and Kim Wylam, SPHR, President and Managing Partner, Baker Tilly Vantagen
In a recent CPA Conversations podcast with the PICPA, Baker Tilly Director, Janice Ahlstrom and Baker Tilly Vantagen President and Managing Partner, Kim Wylam, discuss drug diversion and the important role the formulation of a comprehensive risk and internal audit approach can serve to help prevent and detect drug diversion.
